Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial

By Brian Orelli, PhD – Apr 29, 2020 at 4:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They're off to a fast start, but the companies still have a long ways to go.

It was just last week that Pfizer (PFE) and BioNTech (BNTX) got permission to start a phase 1/2 clinical trial of BNT162, their SARS-CoV-2 vaccine candidate, in Germany.

Seven days later and the companies have already completed inoculating the first group of patients in the study. Of course, that group only consists of 12 participants -- and there are presumably plenty of people eager to participate given the lack of an approved coronavirus vaccine -- but the speed is still impressive nevertheless.

The safety portion of the clinical trial involves testing a range of doses from 1 microgram to 100 micrograms, and will eventually enroll 200 participants. BioNTech has developed four different variations of its mRNA vaccine. For three of the vaccines, the clinical trial will include booster shots after the initial vaccine to hopefully increase the amount of antibodies the participants generate. The fourth vaccine is a self-amplifying mRNA, so the hope is that only a single dose of the vaccine will be required.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Pfizer licensed the rights to BioNTech's coronavirus vaccine in April for $72 million in cash and a $113 million equity investment. BioNTech is also eligible for milestone payments of up to $563 million. The companies will co-market the vaccine worldwide, except in China, where BioNTech licensed it to Fosun Pharma.

Pfizer and BioNTech expect to gain permission from the Food and Drug Administration to expand their clinical trial to the U.S. shortly. There's no word yet on a timeline for the development of the vaccine in China.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
BioNTech SE Stock Quote
BioNTech SE
BNTX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.